Suppr超能文献

慢性肾脏病患者的开窗分支型血管腔内修复术。

Fenestrated-branched endovascular aortic repair in patients with chronic kidney disease.

机构信息

Division of Vascular and Endovascular Surgery, Department of Surgery, UT Southwestern Medical Center, Dallas, Tex.

Division of Vascular and Endovascular Surgery, Department of Surgery, UT Southwestern Medical Center, Dallas, Tex.

出版信息

J Vasc Surg. 2020 Jul;72(1):66-72. doi: 10.1016/j.jvs.2019.09.035. Epub 2020 Feb 13.

Abstract

OBJECTIVE

Renal function impairment is a common complication after open repair of complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms (TAAAs). The purpose of this study was to assess renal perioperative outcomes and renal function deterioration after fenestrated-branched endovascular aneurysm repair (F/BEVAR) in patients with chronic kidney disease (CKD).

METHODS

The study included 186 patients who underwent F/BEVAR between 2013 and 2018 for suprarenal, juxtarenal, and type I to type IV TAAAs. Glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) study equation. Postoperative acute kidney injury (AKI) and CKD were defined using RIFLE criteria (Risk, Injury, Failure, Loss, and End-stage renal disease) and CKD staging system (stage ≥3, GFR <60 mL/min/1.73 m), respectively. For those without baseline CKD, renal decline was defined as a drop in GFR <60 mL/min/1.73 m (ie, progression to CKD stage 3 or higher). For patients with baseline renal dysfunction, GFR decline ≥20% or progression in CKD stage (ie, from stage 3 to stage 4) was considered renal decline.

RESULTS

CKD was present in 83 patients (44.6%). Postoperative AKI was diagnosed in 27 patients (14.5%); 13 (48.1%) had history of CKD and 14 (51.9%) had adequate renal function preoperatively (P = .8). None of these patients required permanent renal replacement therapy. Intraoperative technical success was 100%. Overall 30-day mortality was 1.1%. There was no difference in 30-day mortality in patients with (1.2%) and without (1.0%) CKD (P = .5). During a median follow-up time of 12 months (interquartile range, 6-23 months), renal decline was observed in 21 patients (25.3%) with previous CKD and in 11 patients (10.6%) without CKD (P = .01). Among patients with previous CKD, 18 patients (9%) progressed from stage 3 CKD to stage 4. In patients with progression in CKD stage, two (5%) had renal stent stenosis requiring restenting. Among patients with renal decline, 13 had juxtarenal aneurysms (21.3%), 27 had suprarenal aneurysms (44.3%), and 21 had TAAAs (34.3%; P = .4). Subset analysis of patients who developed AKI in the immediate postoperative period found that patients with a history of CKD were less likely to experience freedom from renal decline.

CONCLUSIONS

F/BEVAR is an effective and safe procedure for patients with complex abdominal aortic aneurysms and TAAAs, even among patients with CKD. The frequency of AKI was not affected by pre-existing CKD. Midterm outcomes demonstrated that progression of CKD was more frequent among patients with pre-existing CKD, but permanent renal replacement therapy was not required. Anatomic extent of aneurysms did not affect CKD progression. CKD patients are susceptible to renal decline over time if they experience AKI in the postoperative period. Therefore, preventing AKI in the postoperative period should be regarded as a priority. Long-term effects of CKD after F/BEVAR remain to be elucidated.

摘要

目的

肾功能损害是复杂的腹主动脉瘤和胸腹主动脉瘤(TAAA)开放修复术后的常见并发症。本研究旨在评估慢性肾脏病(CKD)患者接受腔内分支型血管内修复术(F/BEVAR)后的围手术期肾脏结局和肾功能恶化情况。

方法

本研究纳入了 2013 年至 2018 年间接受 F/BEVAR 治疗的 186 例患者,这些患者患有肾上、肾周和 I 型至 IV 型 TAAA。使用肾脏病膳食改良试验(MDRD)方程计算肾小球滤过率(GFR)。术后急性肾损伤(AKI)和 CKD 分别根据 RIFLE 标准(风险、损伤、衰竭、丢失和终末期肾病)和 CKD 分期系统(≥3 期,GFR<60 mL/min/1.73 m²)进行定义。对于那些没有基线 CKD 的患者,定义为 GFR<60 mL/min/1.73 m²的下降为肾脏下降(即进展为 CKD 3 期或更高)。对于基线肾功能异常的患者,GFR 下降≥20%或 CKD 分期进展(即从 3 期进展至 4 期)被认为是肾脏下降。

结果

83 例患者(44.6%)存在 CKD。术后诊断 AKI 的患者有 27 例(14.5%);13 例(48.1%)有 CKD 病史,14 例(51.9%)术前肾功能正常(P=0.8)。这些患者均未接受永久性肾脏替代治疗。术中技术成功率为 100%。总体 30 天死亡率为 1.1%。有和无 CKD 的患者 30 天死亡率分别为 1.2%和 1.0%(P=0.5)。在中位随访时间 12 个月(四分位距 6-23 个月)期间,21 例(25.3%)既往有 CKD 的患者和 11 例(10.6%)无 CKD 的患者出现了肾脏下降(P=0.01)。在既往有 CKD 的患者中,18 例(9%)从 CKD 3 期进展为 4 期。在 CKD 分期进展的患者中,2 例(5%)因肾支架狭窄需要再次支架置入。在出现肾脏下降的患者中,13 例(21.3%)有肾周动脉瘤,27 例(44.3%)有肾上动脉瘤,21 例(34.3%)有 TAAA(P=0.4)。对术后即刻发生 AKI 的患者进行亚组分析发现,有 CKD 病史的患者发生肾功能下降的可能性较低。

结论

即使在 CKD 患者中,F/BEVAR 也是治疗复杂腹主动脉瘤和 TAAA 的有效且安全的方法。术前 CKD 并不影响 AKI 的发生频率。中期结果表明,术前存在 CKD 的患者 CKD 进展更为常见,但不需要永久性肾脏替代治疗。动脉瘤的解剖范围并不影响 CKD 的进展。如果 CKD 患者术后发生 AKI,随着时间的推移,他们更容易出现肾功能下降。因此,预防术后 AKI 应作为优先事项。F/BEVAR 后 CKD 的长期影响仍有待阐明。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验